The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Evaluating the role of BTK inhibitors in CLL
Nicole Lamanna, MD, Columbia University Medical Center, New York, NY, gives an overview of the key talking points from a symposium at SOHO 2021 on the efficacy and rationale for the use of Bruton’s tyrosine kinase (BTK) inhibitors in different subtypes of chronic lymphocytic leukemia (CLL). Dr Lamanna comments on the safety profiles of different BTK inhibitors, the comparison of ibrutinib with second-generation BTK inhibitors, and the development of novel, non-covalent BTK inhibitors such as pirtobrutinib. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of consultancy and/or advisory work for AbbVie Inc., AstraZeneca, BeiGene, Celgene Corporation, Genentech, Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc. and Pharmacyclics; or institutional grant and/or research support from AbbVie Inc., AstraZeneca, BeiGene, Genentech, Inc., Juno Therapeutics, Inc., Loxo Oncology, MingSight Pharmaceuticals, Inc., Octapharma, Oncternal Therapeutics, and TG Therapeutics, Inc.
